PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 138 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,010,106 | -15.0% | 180,462 | +40.8% | 0.02% | -8.0% |
| Q2 2023 | $3,540,801 | +35.8% | 128,197 | +13.1% | 0.02% | +25.0% |
| Q1 2023 | $2,607,165 | -0.7% | 113,355 | -52.9% | 0.02% | 0.0% |
| Q4 2022 | $2,626,528 | +28.2% | 240,745 | -0.9% | 0.02% | +17.6% |
| Q3 2022 | $2,049,000 | +125.7% | 243,013 | +111.8% | 0.02% | +142.9% |
| Q2 2022 | $908,000 | -68.0% | 114,759 | -4.2% | 0.01% | -61.1% |
| Q1 2022 | $2,838,000 | -30.1% | 119,834 | +0.9% | 0.02% | -30.8% |
| Q4 2021 | $4,060,000 | +221.2% | 118,715 | +66.4% | 0.03% | +188.9% |
| Q3 2021 | $1,264,000 | -76.4% | 71,343 | -40.2% | 0.01% | -74.3% |
| Q2 2021 | $5,358,000 | – | 119,391 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |